ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar s...
ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
About this item
Full title
Author / Creator
Publisher
US: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
US: Oxford University Press
Subjects
More information
Scope and Contents
Contents
Abstract
Purpose
Discontinuation of denosumab (DMab) is associated with rapid declinein bone density. Sequential antiresorptive drugs are recommended to preserve bone mass after DMab treatment. It remains unclear whether raloxifene exclusively can be used in certain conditions to attenuate bone loss after DMab discontinuation.
Methods
I...
Alternative Titles
Full title
ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9624547
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9624547
Other Identifiers
ISSN
2472-1972
E-ISSN
2472-1972
DOI
10.1210/jendso/bvac150.361
